FDA approves Incyte’s Pemazyre for rare bile duct cancerThe FDA has approved Incyte’s Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile Share XFDA approves Incyte’s Pemazyre for rare bile duct cancerhttps://pharmaphorum.com/news/fda-approves-incytes-pemazyre-for-rare-bile-duct-cancer/
